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To the Editor:
We thank Drs Vigano`, Cimino, Adam,and Torzilli for their interest on our
analysis of the ALPPS registry and their
critical points.1
The authors challenge the proposed
criteria to delay the second stage of ALPPS
(completion hepatectomy) in presence of an
Model of End Stage Liver Disease score
greater than 10 and positive International
Study Group of Liver Surgery criteria.2 They
speculate that applying such criteria may
result in a 30% drop-out similar to previous
2-stage hepatectomy. They also suggest
differentiating ‘‘oncological’’ (tumor pro-
gression) versus ‘‘functional (liver failure)
drop-out’’ claiming that the drop-out in
ALPPS is functional, whereas the oncologic
drop-out associated with the standard 2-stage
hepatectomy is rather oncologic leading to
some sort of natural selection.
The main benefit of ALPPS indeed
lies in the shortened interstage interval ena-
bling potentially curative resection with a
reported drop-out rate of only 2% in color-
ectal liver metastases.3 The typical interstage
period of 7 to 10 days in ALPPS have to be 4
to 8 times replicated to reach the reported
interstage time period of conventional 2-
stage hepatectomy.3 In our experience, pro-
longation of interstage interval due to liver
dysfunction exceptionally exceeds 3 weeks,
and therefore still prevents tumor progression
in most cases. The advantage is also on the
oncologic perspective, because adjuvant che-
motherapy cannot be started at an earliest
time in other approaches (Kambakamba P,
Linecker M, Alvarez, FA, et al. ALPPS
reduces chemotherapy-free interval and
may improve oncological outcome in
patients with bilobar colorectal liver meta-
stases, in preparation.).
We agree, however, that oncological
outcome remains one of the hottest topics in
ALPPS. There are currently no convincing
data on the oncological outcome of ALPPS in
comparison with conventional two-stage
hepatectomy, and lacking a randomized con-
trolled trial (RCT), we may only speculate on
the interpretation on any retrospective com-
parison. For example, we attempted—with
one of the coauthors of your letter (R.
Adam)—a case-matched analysis of ALPPS
versus standard two-stage hepatectomy using
the LiverMetSurvey database and the inter-
national ALPPS registry. The retrospective,
voluntary, and missing information in both
registries prevent definitive conclusion,
but only offer a crude evaluation indicating
comparable long-term outcome measures
between both groups. Therefore, we launched
a randomized controlled trial targeting bilat-
eral liver colorectal metastases, which is cur-
rently open to the 230 centers registered in the
ALPPS registry (www.alpps.net).
We agreewith Vigano` et al2 that an age
limitation of 60 years is too restrictive con-
sidering the worldwide aging population.
This cut-off is only indicative of an additional
risk factor, but in no way precludes surgery.
Of note, the most recent safety analysis of the
ALPPS registry, which was presented at the
last annual meeting of the ESA, identified an
age of 67 as best cut-off for predicting
mortality after ALPPS, probably due to the
use of safer surgeries compared to the initial
cases included.4 Therefore, the previous
recommendation on age must be corrected
because almost 25% of patients in this
analysis belonged to the age segment of
60 to 67 years, and would be classified with
an incorrectly high risk.
The authors further propagate their
experience with ultrasound-guided paren-
chyma-sparing one-stage hepatectomy5 as
an effective alternative to two-stage hepatec-
tomy in bilobar colorectal liver metastases. In
our experience, most patients treated with the
ALPPS approach would not qualify for any
types of ‘‘single’’ surgery approach. In
addition, the available comparative studies
experience major selection bias and hetero-
geneity of the study population.
In summary, ALPPS is a young pro-
cedure still in its development phase with
many variants to improve safety.6 The learn-
ing curve is still one of the major determi-
nants of safety; only 10% of the registered
centers in the ALPPS registry have per-
formedmore than 10 cases and 214 registered
centers entered less than 10 cases. Analyses
from the international ALPPS Registry
remain the best available evidence to study
safety and oncological efficacy short of
higher-level evidence studies. Therefore,
the oncological efficacy of ALPPS remains
purely speculative. We agree with the authors
that ALPPS is definitively not a procedure
applicable for all colorectal liver metastases
but is certainly a very useful tool for the
experienced HPB surgeon in a variety of
complex situations including small future
liver remnants in which mono- or bisegment
ALPPS are the only option, failure of portal
vein embolization, or tumors close to import-
ant vascular structures.
Michael Linecker, MD
Henrik Petrowsky, MD
Pierre-Alain Clavien, MD, PhD
Swiss HPB and Transplant Center, University
Hospital Zurich, Zurich, Switzerland
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